Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
THIS MESSAGE BOARD IS NOW EFFECTIVELY CLOSED.
SHPG closes BXLT acquisition: #msg-123065519.
Shire shareholders approve $32 bln Baxalta merger (5/27/16)
By Ian Walker
LONDON--Shareholders of Dublin-based pharmaceutical company Shire PLC SHP Friday approved the company's proposed $32 billion merger with Bannockburn, Ill-based Baxalta Incorporated at the general meeting, and the deal is expected to close on June 3.
Shire Chief Executive Flemming Ornskov said: "The combination will allow us to realize our goal of building the leading global biotechnology company focused on rare diseases and other highly specialized conditions, offering greater opportunities for our patients, healthcare partners and employees."
Shire and Baxalta announced their deal in January. The two companies signed off on the deal after overcoming fears the tie-up could run afoul of U.S. laws that prohibit tax-free spinoffs from being used as a device to funnel cash to shareholders. Baxalta was separated from parent Baxter International Inc. in July.
Shire agreed to pay $18 in cash plus 0.1482 of its American depository shares for each Baxalta share, making it one of the few ever cash-and-stock deals involving a recent tax-free spinoff.
Early last month, the Treasury Department imposed new rules that make it harder for companies to move their tax addresses out of the U.S. and then shift profits to low-tax countries using a maneuver known as earnings stripping.
Completion of the merger remains subject to approval by Baxalta shareholders, with a vote scheduled for 12GMT Friday, and other customary closing conditions, Shire said.
http://www.marketwatch.com/story/shire-shareholders-approve-32-bln-baxalta-merger-2016-05-27
Baxalta Shareholders Vote to Approve Combination (5/27/16)
BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT) today announced the results of a vote on the proposals identified in the definitive proxy statement/prospectus, dated April 18, 2016, at a special meeting of shareholders held earlier this morning relating to the proposed combination with Shire plc (LSE: SHP, NASDAQ: SHPG). Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 98.9 percent of shares outstanding cast in favor of the proposal.
Earlier today, Shire shareholders of approximately 93.8 percent of the votes cast voted in favor of the adoption of the merger agreement with Baxalta. This represents approximately 75.5 percent of Shire’s total outstanding shares of common stock as of 8:00 a.m. (London time) on May 25, 2016, the record date for the special meeting.
As announced on January 11, 2016, Baxalta and Shire entered into a definitive merger agreement pursuant to which Shire would acquire Baxalta in a stock and cash transaction. Baxalta stockholder approval and Shire shareholder approval are conditions to the merger. The completion of the transaction remains subject to certain other closing conditions, but the companies expect that this transaction will be completed on or about June 3, 2016.
About Baxalta
Baxalta Incorporated (NYSE: BXLT) is a global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, immunology and oncology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, with its Global Innovation Center in Cambridge, Mass., Baxalta employs 17,000 employees worldwide.
http://www.businesswire.com/news/home/20160527005380/en/Baxalta-Shareholders-Vote-Approve-Combination
Special Meeting will be held 5/27/16 at 7:00 CT.
BXLT hits new 52-week high (5/25/16)
BAXALTA INCORPORATED (BXLT)
Last Trade [tick] 45.7000[+]
Volume 14,167,409
Net Change -0.0100
Net Change % -0.02%
52 Week High 46.0900 on 05/26/2016
52 Week Low 29.8295 on 07/14/2015
Day High 46.0900
Day Low 45.4900
BXLT hits new 52-week high (5/25/16)
BAXALTA INCORPORATED (BXLT)
Last Trade [tick] 45.7100[+]
Volume 12,687,726
Net Change 0.7100
Net Change % 1.58%
52 Week High 45.7100 on 05/25/2016
52 Week Low 29.8295 on 07/14/2015
Day High 45.7100
Day Low 45.3300
Baxalta Announces Preliminary Merger Consideration Election Results (5/23/16)
BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT) today announced the preliminary results of the elections made by its stockholders as to the form of stock consideration to be received in Baxalta’s merger with Shire plc (LSE: SHP, NASDAQ: SHPG).
As previously announced, upon the consummation of the merger, each outstanding Baxalta share will be converted into the right to receive:
(i) $18.00 in cash, and
(ii) either 0.1482 of a Shire American Depositary Share (a “Shire ADS”), with each Shire ADS representing three ordinary shares of Shire, or if a Baxalta stockholder elects, 0.4446 of an ordinary share of Shire.
Based on available information, the exchange agent for the election process has advised that, as of the election deadline of 5:00 p.m. Eastern Time on May 20, 2016, holders of approximately 41,803,203 Baxalta shares, or approximately 6.10% of the outstanding Baxalta shares, elected to receive ordinary shares of Shire rather than Shire ADSs.
Baxalta stockholders who made an ordinary share election will be unable to sell or otherwise transfer their shares unless the ordinary share election was properly revoked prior to the election deadline or unless the merger agreement is terminated. Baxalta stockholders who did not make an ordinary share election or who properly revoked any such election prior to the election deadline will, by default, receive Shire ADSs in the merger.
About Baxalta
Baxalta Incorporated (NYSE:BXLT) is a global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, immunology and oncology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, with its Global Innovation Center in Cambridge, Mass., Baxalta employs 17,000 employees worldwide.
http://www.businesswire.com/news/home/20160523005463/en/Baxalta-Announces-Preliminary-Merger-Consideration-Election-Results
Exchange Offer had an Odd Lot Preference.
Purchased 99 BAX shares at 44.34 on 4/27/16. These will be exchanged into the equivalent of 114.75 BXLT shares.
Baxalta Announces Date for Special Meeting of Stockholders to Vote on Combination With Shire (4/14/16)
BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT) announced today that the special meeting of stockholders to adopt the merger agreement with Shire plc (LSE:SHP, NASDAQ:SHPG) will be held on May 27, 2016, at 7:00 a.m. Central Time, for shareholders of record as of the close of business on April 11, 2016. The special meeting will be held at Baxalta’s corporate headquarters, located at 1200 Lakeside Drive, Bannockburn, Illinois 60015.
For more information, please refer to the merger proxy on Form S-4 that Shire has filed with the Securities and Exchange Commission (SEC).
About Baxalta
Baxalta Incorporated (NYSE:BXLT) is a global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, immunology and oncology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, with its Global Innovation Center in Cambridge, Mass., Baxalta employs 17,000 employees worldwide.
http://www.businesswire.com/news/home/20160414006544/en/Baxalta-Announces-Date-Special-Meeting-Stockholders-Vote
Baxter Announces Final Exchange Ratio of 1.1591 for Baxalta Exchange Offer (5/17/16)
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) (“Baxter”) announced today the final exchange ratio in connection with its previously announced offer to exchange up to 13,360,527 shares of common stock of Baxalta Incorporated (NYSE: BXLT) (“Baxalta”) that are currently owned by Baxter for shares of Baxter common stock.
For each share of Baxter common stock that is validly tendered and not validly withdrawn by a stockholder and that is accepted by Baxter pursuant to the exchange offer, Baxter will deliver 1.1591 shares of Baxalta common stock to or at the direction of such tendering stockholder.
Based on the final exchange ratio, Baxter will accept for exchange 11,526,638 shares of its common stock if the exchange offer is fully subscribed. Because the exchange offer will be subject to proration if the exchange offer is oversubscribed, the number of shares of Baxter common stock accepted in the exchange offer may be fewer than the number of shares tendered.
The exchange offer and withdrawal rights are scheduled to expire at 11:59 p.m., New York City time, on Wednesday, May 18, 2016, unless the exchange offer is extended or terminated. Accordingly, Baxter stockholders may tender or withdraw their shares of Baxter common stock until that time by following the procedures described in the prospectus and related letter of transmittal. The completion of the exchange offer is subject to certain conditions as set forth in the prospectus.
For more information about the exchange offer, please contact the information agent, D.F. King.
About Baxter
Baxter International Inc. (NYSE: BAX) provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. Baxter’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon Baxter’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
http://www.businesswire.com/news/home/20160517005420/en/Baxter-Announces-Final-Exchange-Ratio-1.1591-Baxalta
$BXLT recent news/filings
bullish 39.06
## source: finance.yahoo.com
$BXLT charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$BXLT company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/BXLT/company-info
Ticker: $BXLT
OTC Market Place: Not Available
CIK code: 0001620546
Company name: Baxalta Incorporated
Incorporated In: DE, USA
$BXLT share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$BXLT extra dd links
Company name: Baxalta Incorporated
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=BXLT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=BXLT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=BXLT+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/BXLT/news - http://finance.yahoo.com/q/h?s=BXLT+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/BXLT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/BXLT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=BXLT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/BXLT
DTCC (dtcc.com): http://search2.dtcc.com/?q=Baxalta+Incorporated&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Baxalta+Incorporated
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Baxalta+Incorporated&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/BXLT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001620546&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/BXLT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/BXLT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=BXLT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=BXLT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/BXLT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=BXLT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=BXLT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=BXLT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=BXLT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=BXLT+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/BXLT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=BXLT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/BXLT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=BXLT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/BXLT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/BXLT/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/BXLT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/BXLT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/BXLT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=BXLT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=BXLT
$BXLT DD Notes ~ http://www.ddnotesmaker.com/BXLT
Baxalta ($BXLT) reported better than expected fourth quarter earnings per share and revenues. The company's first quarter guidance is weak.
SHPG acquires BXLT in cash+stock deal: #msg-119740938.
Two Approvals Mark a Busy Week at the FDA - article discusses Baxalta
http://marketexclusive.com/two-approvals-mark-a-busy-week-at-the-fda/1149/
FDA approves Vonvendi for von Willebrand disease: #msg-119018462.
BXLT is an solid stock.. Good growing potential.. Did you see JuNo?
SHPG offers to acquire BXLT for $45.23/sh in stock: #msg-115927095.
BXLT authorizes $1B buyback plan:
http://finance.yahoo.com/news/baxalta-board-directors-declares-inaugural-200600080.html
BXLT—pharma spin-off from BAX—launches as independent company:
http://finance.yahoo.com/news/baxalta-launches-global-biopharmaceutical-leader-110000234.html
Please see #msg-114360736 for background info.
New interim data on Factor-IX gene therapy: #msg-114889445.
BXLT selling $5B of debt (to prepare for 7/1/15 separation from BAX):
http://finance.yahoo.com/news/baxalta-announces-pricing-5-billion-120000006.html
BXLT Investor Day slide sets…
Overview:
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9Mjg3NTE4fENoaWxkSUQ9LTF8VHlwZT0z&t=1
Pipeline:
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9Mjg3NTIxfENoaWxkSUQ9LTF8VHlwZT0z&t=1
Other slide sets:
http://phx.corporate-ir.net/phoenix.zhtml?c=86121&p=irol-2015-Investor-Conference-Baxalta
Followers
|
0
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
23
|
Created
|
05/22/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |